Passing 340B drug discounts to patients with COPD so they can buy inhalers at a much lower cost yielded positive outcomes both for the patients and the hospitals that serve them, new research shows.
Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings
Views
Two new studies—one by pharmacists at Ascension Via Christi health system in Kansas, the other by drug industry consulting and [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.